EA020479B1 - СОЕДИНЕНИЯ И КОМПОЗИЦИИ КАК ИНГИБИТОРЫ ПРОТЕИНКИНАЗЫ B-Raf - Google Patents

СОЕДИНЕНИЯ И КОМПОЗИЦИИ КАК ИНГИБИТОРЫ ПРОТЕИНКИНАЗЫ B-Raf Download PDF

Info

Publication number
EA020479B1
EA020479B1 EA201200323A EA201200323A EA020479B1 EA 020479 B1 EA020479 B1 EA 020479B1 EA 201200323 A EA201200323 A EA 201200323A EA 201200323 A EA201200323 A EA 201200323A EA 020479 B1 EA020479 B1 EA 020479B1
Authority
EA
Eurasian Patent Office
Prior art keywords
alkyl
methyl
pyrimidin
cyclopropyl
propan
Prior art date
Application number
EA201200323A
Other languages
English (en)
Russian (ru)
Other versions
EA201200323A1 (ru
Inventor
Абран К. Косталес
Шэньлинь Хуан
Джефф Цзинь (Сяньмин)
Зуошэн Лю
Сабина Пекки
Даниел Пун
Джон Теллью
Цион Чжан
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201200323A1 publication Critical patent/EA201200323A1/ru
Publication of EA020479B1 publication Critical patent/EA020479B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA201200323A 2009-08-28 2010-08-26 СОЕДИНЕНИЯ И КОМПОЗИЦИИ КАК ИНГИБИТОРЫ ПРОТЕИНКИНАЗЫ B-Raf EA020479B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23808309P 2009-08-28 2009-08-28
US31306110P 2010-03-11 2010-03-11
PCT/EP2010/062495 WO2011023773A1 (en) 2009-08-28 2010-08-26 Compounds and compositions as protein kinase inhibitors

Publications (2)

Publication Number Publication Date
EA201200323A1 EA201200323A1 (ru) 2012-09-28
EA020479B1 true EA020479B1 (ru) 2014-11-28

Family

ID=42829939

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201200323A EA020479B1 (ru) 2009-08-28 2010-08-26 СОЕДИНЕНИЯ И КОМПОЗИЦИИ КАК ИНГИБИТОРЫ ПРОТЕИНКИНАЗЫ B-Raf

Country Status (19)

Country Link
US (3) US8242260B2 (pl)
EP (1) EP2470528B1 (pl)
JP (1) JP5726190B2 (pl)
KR (1) KR101714107B1 (pl)
CN (1) CN102596937B (pl)
AR (1) AR077977A1 (pl)
AU (1) AU2010288455B2 (pl)
BR (1) BR112012004448A2 (pl)
CA (1) CA2771673C (pl)
EA (1) EA020479B1 (pl)
ES (1) ES2527176T3 (pl)
IN (1) IN2012DN00869A (pl)
JO (1) JO3007B1 (pl)
MX (1) MX2012002542A (pl)
PL (1) PL2470528T3 (pl)
PT (1) PT2470528E (pl)
TW (1) TWI487701B (pl)
UY (1) UY32859A (pl)
WO (1) WO2011023773A1 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
MX340392B (es) 2010-02-25 2016-07-06 Dana Farber Cancer Inst Inc Mutaciones del protooncogen de serina/treonina-proteina cinasa b-raf (braf) que confieren resistencia a los inhibidores del protooncogen de serina/treonina-proteina cinasa b-raf.
WO2013059634A1 (en) 2011-10-20 2013-04-25 The Regents Of The University Of California Use of cdk9 inhibitors to reduce cartilage degradation
CN108542906A (zh) 2011-11-11 2018-09-18 诺华股份有限公司 治疗增生性疾病的方法
SI2782557T1 (sl) 2011-11-23 2019-02-28 Array Biopharma, Inc., Farmacevtske formulacije
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
US20150232452A1 (en) * 2012-09-19 2015-08-20 Ruga Corporation Novel raf kinase inhibitors
US9242969B2 (en) * 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
CN105228983A (zh) 2013-05-30 2016-01-06 普莱希科公司 用于激酶调节的化合物及其适应症
MX2015016771A (es) 2013-06-25 2016-03-31 Squibb Bristol Myers Co Compuestos de carbazol carboxamida utiles como inhibidores de cinasa.
UY35625A (es) 2013-06-25 2014-12-31 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos como inhibidores de quinasa
KR20160067841A (ko) * 2013-08-28 2016-06-14 메디베이션 테크놀로지즈, 인크. 헤테로사이클릭 화합물 및 사용 방법
GB2517988A (en) * 2013-09-09 2015-03-11 Redx Pharma Ltd Compounds
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
JP6930913B2 (ja) 2014-10-14 2021-09-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ 炎症を阻害するためのｃｄｋ９及びｂｒｄ４阻害剤の使用法
CN104402920B (zh) * 2014-11-27 2018-04-03 河南科技学院 一种合成2‑卤代‑3‑频那醇硼酸酯‑5‑氯苯胺的方法
AU2017329090B9 (en) 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
JP7341060B2 (ja) 2017-02-10 2023-09-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｍａｐｋ経路の活性化に関連付けられる癌の処置のための方法及び医薬組成物
JP7309614B2 (ja) 2017-05-02 2023-07-18 ノバルティス アーゲー 組み合わせ療法
EP3732285A1 (en) 2017-12-28 2020-11-04 Tract Pharmaceuticals, Inc. Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
WO2020124397A1 (en) * 2018-12-19 2020-06-25 Inventisbio Shanghai Ltd. C-terminal src kinase inhibitors
WO2022036176A1 (en) * 2020-08-13 2022-02-17 Albert Einstein College Of Medicine N-cyclyl-sulfonamides useful for inhibiting raf
WO2023240024A1 (en) 2022-06-08 2023-12-14 Nikang Therapeutics, Inc. Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009115572A2 (en) * 2008-03-21 2009-09-24 Novartis Ag Novel heterocyclic compounds and uses therof
WO2009137391A2 (en) * 2008-05-06 2009-11-12 Smithkline Beecham Corporation Benzene sulfonamide thiazole and oxazole compounds
WO2010010154A1 (en) * 2008-07-24 2010-01-28 Nerviano Medical Sciences S.R.L. 3,4-diarylpyrazoles as protein kinase inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2659739A (en) 1950-04-14 1953-11-17 Eastman Kodak Co 1-hydroxy-4-beta-cyanopropylamino-anthraquinone and process for preparing same
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6037136A (en) 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
GB2306108A (en) * 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
JP2000511419A (ja) 1996-05-23 2000-09-05 アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ Ｒａｆ―１または１４―３―３タンパク質のＩＬ―２受容体β鎖への結合を阻害する化合物およびそれを含有する医薬組成物
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6204467B1 (en) 1998-03-24 2001-03-20 Ford Global Technologies, Inc. Method and apparatus for resistive welding
ME00275B (me) 1999-01-13 2011-02-10 Bayer Corp ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
AU2001285349A1 (en) 2000-08-30 2002-03-13 The Board Of Trustees Of The University Of Arkansas Induction of ldl receptor expression by extracellular-signal regulated kinase, erk-1/2
SI2130537T1 (sl) 2002-03-13 2013-01-31 Array Biopharma, Inc. N3-alkilirani derivati benzimidazola kot inhibitorji mek
US6644516B1 (en) 2002-11-06 2003-11-11 Continental Afa Dispensing Company Foaming liquid dispenser
CA2599320A1 (en) 2005-02-25 2006-08-31 Kudos Pharmaceuticals Limited Hydrazinomethyl, hydr zonomethyl and 5-membered heterocylic compounds which act as mtor inhibitors and their use as anti cancer agents
JP2008531538A (ja) 2005-02-25 2008-08-14 クドス ファーマシューティカルズ リミテッド ２，４−ジアミノ−ピリドピリミジン誘導体とｍＴＯＲ阻害剤としてのその使用
WO2007060404A1 (en) 2005-11-22 2007-05-31 Kudos Pharmaceuticals Limited PYRIDO-,PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
AU2007204208A1 (en) 2006-01-11 2007-07-19 Astrazeneca Ab Morpholino pyrimidine derivatives and their use in therapy
HUE033894T2 (en) 2006-08-23 2018-01-29 Kudos Pharm Ltd 2-Methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as MTOR inhibitors
TW200922582A (en) 2007-08-20 2009-06-01 Organon Nv N-benzyl, N'-arylcarbonylpiperazine derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009115572A2 (en) * 2008-03-21 2009-09-24 Novartis Ag Novel heterocyclic compounds and uses therof
WO2009137391A2 (en) * 2008-05-06 2009-11-12 Smithkline Beecham Corporation Benzene sulfonamide thiazole and oxazole compounds
WO2010010154A1 (en) * 2008-07-24 2010-01-28 Nerviano Medical Sciences S.R.L. 3,4-diarylpyrazoles as protein kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WOLIN R.L. ET AL.: "Dual binding site inhibitors of B-RAF kinase" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB LNKD- DOI:10.1016/J.BMCL.2008.04.002, vol. 18, no. 9, 1 May 2008 (2008-05-01), pages 2825-2829, XP022634962 ISSN: 0960-894X [retrieved on 2008-04-04] page 2827; table 1; compounds 14-16 *

Also Published As

Publication number Publication date
WO2011023773A1 (en) 2011-03-03
TWI487701B (zh) 2015-06-11
EP2470528B1 (en) 2014-10-01
ES2527176T3 (es) 2015-01-21
CN102596937B (zh) 2014-02-12
TW201111365A (en) 2011-04-01
JO3007B1 (ar) 2016-09-05
JP2013503139A (ja) 2013-01-31
AU2010288455B2 (en) 2013-01-31
CA2771673C (en) 2016-07-12
US8242260B2 (en) 2012-08-14
KR101714107B1 (ko) 2017-03-08
KR20120092577A (ko) 2012-08-21
BR112012004448A2 (pt) 2017-05-30
AU2010288455A1 (en) 2012-02-23
EA201200323A1 (ru) 2012-09-28
UY32859A (es) 2011-03-31
CA2771673A1 (en) 2011-03-03
US8859548B2 (en) 2014-10-14
US8563553B2 (en) 2013-10-22
US20110052578A1 (en) 2011-03-03
EP2470528A1 (en) 2012-07-04
IN2012DN00869A (pl) 2015-07-10
US20120225899A1 (en) 2012-09-06
MX2012002542A (es) 2012-04-02
CN102596937A (zh) 2012-07-18
JP5726190B2 (ja) 2015-05-27
PL2470528T3 (pl) 2015-03-31
AR077977A1 (es) 2011-10-05
US20140011825A1 (en) 2014-01-09
PT2470528E (pt) 2014-12-29

Similar Documents

Publication Publication Date Title
EA020479B1 (ru) СОЕДИНЕНИЯ И КОМПОЗИЦИИ КАК ИНГИБИТОРЫ ПРОТЕИНКИНАЗЫ B-Raf
JP6667573B2 (ja) 新規なアミノピリミジン誘導体
AU2019358948B2 (en) STING Agonistic Compound
AU2010286569B2 (en) Compounds and compositions as protein kinase inhibitors
CN105683166B (zh) 取代的嘧啶Bmi-1抑制剂
WO2021173923A1 (en) Pyrrolidine-fused heterocycles
JP2017530984A (ja) ヒストンデメチラーゼのインヒビターとしてのピロリドンアミド化合物
KR20130130030A (ko) Vps34 억제제로서의 비-헤테로아릴 화합물
KR20220161396A (ko) 치환된 피리디논-피리디닐 화합물의 제조, 조성물, 및 결정형
US20160272635A1 (en) Substituted dihydropyrido[3,4-b]pyrazinones as dual inhibitors of bet proteins and polo-like kinases
MXPA05005477A (es) Pirimidinas 2,4,6-trisustituidas como inhibidores de fosfotidilinositol (pi) 3-cinasa y su uso en el tratamiento del cancer.
JP6782766B2 (ja) ヒト免疫不全ウイルス複製の阻害剤としての５−（ｎ−ベンジルテトラヒドロイソキノリン−６−イル）ピリジン−３−イル酢酸誘導体
JP2016511262A (ja) 置換二環式ジヒドロピリミジノン及び好中球エラスターゼ活性の阻害薬としてのそれらの使用
JP6333996B2 (ja) がんを予防または治療するための、ブロモドメイン阻害化合物およびそれを含む医薬組成物
AU2016301212A1 (en) Inhibitors of ACK1/TNK2 tyrosine kinase
CN117500507A (zh) 作为新的sos1抑制剂的磷衍生物
KR20240026948A (ko) 황 함유 헤테로방향족 트리사이클릭 kras 억제제
US20230295166A1 (en) Atr inhibitors and uses thereof
US20230339927A1 (en) Atr inhibitors and uses thereof
ES2904843T3 (es) Compuestos inhibidores de BTK
TW202322808A (zh) 治療疾病之化合物、組合物及方法

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU